Quick-Start contraception: a new pill may stop ovulation sooner
NCT ID NCT06396208
First seen Aug 19, 2026 · Last updated Aug 26, 2026 · Updated 3 times
Summary
This trial tests whether a quadriphasic contraceptive pill (estradiol valerate/dienogest) can inhibit ovulation when started on days 7-9 of the menstrual cycle, compared to a standard pill (ethinylestradiol/gestodene). Forty women aged 18-45 will take one of the two pills starting mid-cycle, and researchers will monitor ovulation via ultrasound and blood tests. The goal is to see if the new pill works as well as the standard one for 'quick-starting' contraception.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Quadriphasic estradiol valerate/dienogest (a combined oral contraceptive pill)
- What this could lead to
- If successful, this could offer a more flexible option for starting birth control pills mid-cycle, potentially reducing the need for backup contraception.
- What could go wrong
- This is a small, early-stage trial (40 participants) and may not reflect real-world effectiveness. The quick-start method could cause irregular bleeding or other side effects, and ovulation inhibition may not be as reliable as the standard pill.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Oct 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 18 - 45 years old * Body mass index 18-30 kg/m² * Menstrual interval within 24 - 38 days * Absence of history of estrogen or progestin allergy and Absence of these compatibles with U.S. medical eligibility criteria category 3 - 4 * Consent to use condom as contraception or have been sterilized Exclusion Criteria: * History of estrogen, progestin or testosterone use within 3 months * Current pregnant or within 3 months of breastfeeding * Having ovarian cyst(s) or tumor(s) * Being a cervical cancer patient or having precancerous cervical lesion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical mucus are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
King Chulalongkorn Memorial Hospital
Bangkok, 10330, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.